Prostatic Neoplasms Clinical Trials in Nashville, Tennessee

4 studies are recruiting for prostatic neoplasms in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    SCRI Oncology Partners ( Site 0074), Nashville, Tennessee
    Locations
    298 in total
    Run by
    Merck Sharp & Dohme LLC
  2. Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

    The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Urology Associates of Nashville, Nashville, Tennessee
    Locations
    34 in total
    Run by
    Clarity Pharmaceuticals Ltd
  3. A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

    The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Tennessee Oncology, Nashville, Tennessee
    Locations
    19 in total
    Run by
    Janssen Research & Development, LLC
  4. A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

    The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRP…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Tennessee Oncology, Nashville, Tennessee
    Locations
    10 in total
    Run by
    Flare Therapeutics Inc.

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.